Abbvie CDR【ABBV】銘柄情報

Abbvie CDR (ABBV) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

31.80

( 1.21% )

買値

31.66

売値

31.85

出来高

4,380

31.65 日の範囲 32.13

0.00 52 週間の範囲 0.00

時価総額

56.184B

前日終値

31.42

始値

32.00

時刻

100

31.8

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

$ 6,686,357

発行済株式数

1,766,792,821

配当利回り

6.74 (3.28%)

PER

107.25

1 株当たり利益 (EPS)

2.03

歳入

62.82B

純利益

3.64B

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment... AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. 詳細を表示

セクター

Healthcare

業界

Pharmaceuticals

ウェブサイト

www.abbvie.com

本社

North Chicago, United States

設立

2026

Abbvie CDR is listed in the Healthcare sector of the トロント証券取引所 with ticker ABBV. The last closing price for Abbvie CDR was $31.42. Over the last year, Abbvie CDR shares have traded in a share price range of $ 0.00 to $ 0.00.

Abbvie CDR currently has 1,766,792,821 shares in issue. The market capitalisation of Abbvie CDR is $56.18 billion. Abbvie CDR has a price to earnings ratio (PE ratio) of 107.25.

表示するニュースはありません。